Notice2024-01723
Agency Information Collection Activities: Proposed Collection; Comment Request
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 29, 2024
Issuing agencies
Health and Human Services DepartmentCenters for Medicare & Medicaid Services
Abstract
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 19 (Monday, January 29, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 19 (Monday, January 29, 2024)]
[Notices]
[Pages 5548-5549]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-01723]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifiers: CMS-10858, CMS-10215 and CMS-10394]
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Centers for Medicare & Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is
announcing an opportunity for the public to comment on CMS' intention
to collect information from the public. Under the Paperwork Reduction
Act of 1995 (PRA), Federal agencies are required to publish notice in
the Federal Register concerning each proposed collection of information
(including each proposed extension or reinstatement of an existing
collection of information) and to allow 60 days for public comment on
the proposed action. Interested persons are invited to send comments
regarding our burden estimates or any other aspect of this collection
of information, including the necessity and utility of the proposed
information collection for the proper performance of the agency's
functions, the accuracy of the estimated burden, ways to enhance the
quality, utility, and clarity of the information to be collected, and
the use of automated collection techniques or other forms of
information technology to minimize the information collection burden.
DATES: Comments must be received by March 29, 2024.
ADDRESSES: When commenting, please reference the document identifier or
OMB control number. To be assured consideration, comments and
recommendations must be submitted in any one of the following ways:
1. Electronically. You may send your comments electronically to
<a href="http://www.regulations.gov">http://www.regulations.gov</a>. Follow the instructions for ``Comment or
Submission'' or ``More Search Options'' to find the information
collection document(s) that are accepting comments.
2. By regular mail. You may mail written comments to the following
address: CMS, Office of Strategic Operations and Regulatory Affairs,
Division of Regulations Development, Attention: Document Identifier/OMB
Control Number: __, Room C4-26-05, 7500 Security Boulevard, Baltimore,
Maryland 21244-1850.
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, please access
the CMS PRA website by copying and pasting the following web address
into your web browser: <a href="https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing">https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing</a>.
FOR FURTHER INFORMATION CONTACT: William N. Parham at (410) 786-4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the use and burden associated
with the following information collections. More detailed information
can be found in each collection's supporting statement and associated
materials (see ADDRESSES).
CMS-10858 Rebate Reduction Requests under Sections 11101 and 11102 of
the Inflation Reduction Act
CMS-10215 Identifying Medicaid Payment for Physician Administered Drugs
CMS-10394 Application To Be a Qualified Entity to Receive Medicare Data
for Performance Measurement/Reapplication/Annual Report Worksheet
Under the PRA (44 U.S.C. 3501-3520), Federal agencies must obtain
approval from the Office of Management and Budget (OMB) for each
collection of information they conduct or sponsor. The term
``collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA requires Federal agencies
to publish a 60-day notice in the Federal Register concerning each
proposed collection of information, including each proposed extension
or reinstatement of an existing collection of information, before
submitting the collection to OMB for approval. To comply with this
requirement, CMS is publishing this notice.
Information Collection
1. Type of Information Collection Request: New collection (Request
for a new OMB control number); Title of Information Collection: Rebate
Reduction Requests under Sections 11101 and 11102 of the Inflation
Reduction Act; Use: Under the authority in sections 11101 and 11102 of
the Inflation Reduction Act of 2022 (Pub. L. 117-169), the Centers for
Medicare & Medicaid Services (CMS) is implementing the Medicare Part B
Drug Inflation Rebate Program and the Medicare Part D Drug Inflation
Rebate Program codified in section 1847A(i) and section 1860D-14B of
the Social Security Act (``the Act''), respectively. In accordance with
section 1847A(i) of the Act, for calendar quarters beginning January 1,
2023, a manufacturer of a Part B rebatable drug will owe a rebate, to
be deposited in the Federal Supplementary Medical Insurance Trust Fund,
if the amount specified in section 1847A(i)(3)(A)(ii)(I) of the Act
exceeds the inflation-adjusted payment amount, which is calculated as
set forth in section 1847A(i)(3)(C) of the Act. A ``Part B rebatable
drug'' means a single-source drug or biological product (as defined
section 1847A(c)(6)(D) of the Act), including a biosimilar biological
product (as defined section 1847A(c)(6)(H) of the Act) but excluding a
qualifying biosimilar biological product (as defined section
1847A(b)(8)(B)(iii) of the Act), for which payment is made under
Medicare Part B, except such term shall not include such a drug or
biological product if, as determined by the Secretary, the average
total allowed charges for such drug or biological product under Part B
for a year per individual that uses such a drug or biological product
are less than the applicable threshold; or that is a vaccine described
in subparagraph (A) or (B) of section 1861(s)(10) of the Act. In
accordance with Section 1860D-14B of the Act, for each 12-month
applicable period, starting with the applicable period beginning
October 1, 2022, a manufacturer of a Part D rebatable drug will owe a
rebate, to be deposited in the Federal Supplementary Medical Insurance
Trust Fund, if the annual
[[Page 5549]]
manufacturer price exceeds the inflation-adjusted payment amount.
Section 1860D-14B(g)(1)(A) of the Act defines a ``Part D rebatable
drug,'' in part, as a drug or biological described at section 1860D-
14B(g)(1)(C) that is a ``covered Part D drug'' as that term is defined
in section 1860D-2(e) of the Act. The definition of a Part D rebatable
drug includes generic drugs that meet certain statutory criteria
(effectively sole source generics). The definition of a Part D
rebatable drug does not include a drug or biological if, as determined
by the Secretary, the ``average annual total cost'' for such drug or
biological under Part D for a year per individual that uses such a drug
or biological is less than the applicable threshold.
Sections 1847A(i)(3)(G)(ii) and 1860D-14B(b)(1)(C)(ii) of the Act
require that CMS reduce or waive the inflation rebate amount owed (if
any) for a Part B rebatable biosimilar biological product and generic
Part D rebatable drug or biosimilar when CMS determines there is a
severe supply chain disruption during a calendar quarter or applicable
period, respectively, such as that caused by a natural disaster or
other unique or unexpected event. CMS must also reduce or waive the
inflation rebate amount owed (if any) for a generic Part D rebatable
drug if CMS determines that without such reduction or waiver, the drug
is likely to be in shortage in a subsequent applicable period, as
required by section 1860D-14B(b)(1)(C)(iii) of the Act.
CMS does not have information necessary to determine whether
manufacturers of Part B and Part D rebatable drugs should have their
rebate amount reduced due to either a severe supply chain disruption or
a likely shortage as required by sections 1847A(i)(3)(G)(ii), 1860D-
14B(b)(1)(C)(ii), and 1860D-14B(b)(1)(C)(iii) of the Act. Some of the
information and supporting documentation needed for CMS to make a
determination regarding a severe supply chain disruption and the
likelihood of a future shortage are held by manufacturers and are not
available to CMS. As such, for CMS to determine whether there is a
severe supply chain disruption or likelihood of future shortage, in
accordance with sections 1847A(i)(3)(G)(ii), 1860D-14B(b)(1)(C)(ii),
and 1860D-14B(b)(1)(C)(iii) of the Act, a manufacturer must submit to
CMS a request for a rebate reduction along with supporting
documentation. Form Number: CMS-10858 (OMB control number: 0938-New);
Frequency: Once; Affected Public: Private sector and business or other
for-profits; Number of Respondents: 10; Total Annual Responses: 20;
Total Annual Hours: 620. (For policy questions regarding this
collection contact Elisabeth Daniel at 667-290-8793.)
2. Type of Information Collection Request: Extension of currently
approved collection; Title of Information Collection: Identifying
Medicaid Payment for Physician Administered Drugs; Use: States are
required to provide for the collection and submission of utilization
data for certain physician-administered drugs in order to receive
Federal financial participation for these drugs. Physicians, serving as
respondents to States, submit National Drug Code numbers and
utilization information for ``J'' code physician-administered drugs so
that the States will have sufficient information to collect drug rebate
dollars. Form Number: CMS-10215 (OMB control number: 0938-1026);
Frequency: Weekly; Affected Public: Business or other for-profits and
not-for-profit institutions); Number of Respondents: 26,000; Total
Annual Responses: 39,053,932; Total Annual Hours: 162,074. (For policy
questions regarding this collection contact Michael Forman at 410-786-
2666.)
2. Type of Information Collection Request: Revision with change of
a currently approved collection; Title of Information Collection:
Application to be a Qualified Entity to Receive Medicare Data for
Performance Measurement/Reapplication/Annual Report Worksheet; Use: The
Patient Protection and Affordable Care Act (ACA) was enacted on March
23, 2010 (Pub. L. 111-148). ACA amends section 1874 of the Social
Security Act by adding a new subsection (e) to make standardized
extracts of Medicare claims data under Parts A, B, and D available to
QEs to evaluate the performance of providers of services and suppliers.
This is the Application, Reapplication, and ARW which provides CMS with
the information it needs to determine whether an organization earns
approval and continues as a QE.
CMS established the Qualified Entity Certification Program (QECP)
to evaluate an organization's eligibility across three areas: (1)
organizational and governance capabilities, (2) addition of claims data
from other sources (as required in the statute), and (3) data privacy
and security. QE certification lasts for 3 years. Organizations that
are interested in remaining in the QE program must submit a
Reapplication that is reviewed and approved by QECP. In addition, each
year QEs must submit an annual report to QECP that provides information
required by statute. Form Number: CMS-10394 (OMB control number: 0938-
1144); Frequency: Yearly; Affected Public: Business or other for-
profits; Number of Respondents: 40; Total Annual Responses: 210; Total
Annual Hours: 17,400. (For policy questions regarding this collection
contact Kari Gaare at <a href="/cdn-cgi/l/email-protection#c7aca6b5aee9a0a6a6b5a287a4aab4e9afafb4e9a0a8b1"><span class="__cf_email__" data-cfemail="8be0eaf9e2a5eceaeaf9eecbe8e6f8a5e3e3f8a5ece4fd">[email protected]</span></a>).
Dated: January 24, 2024.
William N. Parham, III
Director, Division of Information Collections and Regulatory Impacts,
Office of Strategic Operations and Regulatory Affairs.
[FR Doc. 2024-01723 Filed 1-26-24; 8:45 am]
BILLING CODE 4120-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 29, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.